Systemic Corticosteroids: The Importance of Limiting Their Use in Asthma
- 6 February 2025
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (2) , 308-309
Abstract
No abstract availableFunding Information
- National Heart, Lung, and Blood Institute (4UH3HL151297-04)
- Eli Lilly and Company
- Patient-Centered Outcomes Research Institute
- Colorado Department of Public Health and Environment
This publication has 9 references indexed in Scilit:
- Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for AsthmaNew England Journal of Medicine, 2022
- Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with AsthmaNew England Journal of Medicine, 2022
- Low-dose oral corticosteroids in asthma associates with increased morbidity and mortalityEuropean Respiratory Journal, 2022
- SMART for the treatment of asthma: A network meta-analysis of real-world evidenceRespiratory Medicine, 2021
- Quantification of Glucocorticoid-Associated Morbidity in Severe Asthma Using the Glucocorticoid Toxicity IndexThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programmeEuropean Respiratory Journal, 2020
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysisAnnals of the Rheumatic Diseases, 2017